Boston Scientific
BSX
Performance
About Boston Scientific
Boston Scientific is a global medical device company that develops and manufactures innovative medical solutions to improve health outcomes for patients worldwide. The company offers products and therapies across multiple medical specialties, including cardiovascular, electrophysiology, neuro-modulation, urology, gastroenterology, and cancer treatment, serving healthcare professionals and patients globally. Its focus spans diagnostic and therapeutic devices, implants, and related customer support and education initiatives aimed at advancing patient care and safety. Headquartered with a worldwide presence, Boston Scientific emphasizes corporate responsibility, professional education, and patient resources to support clinicians and caregivers.
Recent News
Culturally Tailored Meals Improve HF Outcomes in Navajo Residents
Boston Scientific's EKOS System Cuts Pulmonary Embolism Mortality by 61% in HI-PEITHO Trial
FDA Issues Alert for Abiomed Heart Pump Controllers
Stryker to Pay Up to $835 Million for Amplitude Vascular, Expanding Lithotripsy Portfolio
New Coronary IVL Tech From Boston Scientific Impresses in First-in-Human Study
Boston Scientific Knew of Pacemaker Battery Problems for Years
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
The Week’s 10 Biggest Funding Rounds: Massive Deals For Medical Devices, Futuristic AI Gadgets And Frontier Labs Lead
Stryker Closes Amplitude Vascular Acquisition
US Stocks Today: US Market Rises on Iran Ceasefire Extension and Solid Earnings
In the Clinic for May 20, 2026
Stocks Give up Their Gains — Plus, an Early Trend We're Watching This Earnings Season
Medtronic Buys CathWorks for $585M to Add AI Cardiovascular Diagnostics
Abbott Launches New Cardiovascular Diagnostics and Wearables, Expanding Digital Health Portfolio
Value, Focus, and the Future of MedTech: M&A and Divestitures Are Rewriting the Strategic Playbook.
Elutia Inc (ELUT) Q1 2026 Earnings Call Transcript
Boston Scientific Plans $88.5M R&D Expansion in Ireland
AIP to Take Avanos Medical Private in $1.27 B Deal
Boston Scientific Posts Positive Data for Coronary IVL Catheter
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Boston Scientific Investors Face May 4 Deadline to Lead $‑Billion Securities‑Fraud Class Action
US Stocks Today: Dow Posts Closing Record High, S&P 500, Nasdaq Muted as AI Rally Pauses
GE Vernova Jumps 13% on Earnings Beat, Propelling U.S. Stocks to New Highs
Dow Adds 160, Nasdaq Falls 134, S&P 500 Loses 5
Next Step in Recycling More Healthcare Plastics: Better Labeling
Here’s What Piper Sandler Thinks About Boston Scientific Corp (BSX) Now
PFA Has Been a Game-Changer for Heart Patients—But There Are Still Risks
Boston Scientific Slashes 2026 Guidance
The Zacks Analyst Blog Highlights Apple, TotalEnergies, Boston Scientific and Good Times Restaurants
Charlotte Emerging as a Global Leader in Health Care Innovation and Med Tech
Boston Scientific Plans Indiana Distribution Center, 300 New Jobs
FDA Warns Device Manufacturers of Nitrosamine Impurities that Could Cause Cancer
Rare Fatal Arrhythmias After PFA Highlighted in MAUDE Analysis
Tutor Intelligence Opens U.S.’s Largest Robot Data Factory in Massachusetts
FDA Issues Most Serious Recall for Certain Pacemaker Devices by Boston Scientific
#58797
Medtronic Bets on Cardiovascular Realignment Amid Stock Pressure and Facility Closures
Jim Cramer Says Today’s Market Is Punishing Stocks Harder than 1999
Boston Scientific Pacemakers Recalled Again—Software Update Now Available
Boston Scientific Corporation (BSX): Billionaire Tom Steyer Is Loading Up on This Stock
How to Invest in Healthcare's Powerful Growth
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification
Stock Market Records, Iran Updates, and Tesla Earnings: What to Watch This Week
LAA Closure Superior to Anticoagulation for Bleeding in AF
Labcorp Expands Epic Pact to Make Full Test Menu Available on Aura
Medtronic Posts 8.4% FY26 Revenue Rise – Highest in a Decade
AI in Transplant Diagnostics: Turning Complexity Into Clinical Clarity
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Boston Scientific Invests $1.5B in MiRus with Option to Buy Its TAVR Business
InsideArbitrage Event Driven Monitor – May 8, 2026
Recent Deals
Boston Scientific Invests $1.5B in MiRus, Secures Option to Acquire Its TAVR Technology
Boston Scientific to Acquire Penumbra in Mixed Cash‑Stock Deal
Boston Scientific Invests $1.5B for 34% Stake in MiRus
Boston Scientific Completes Acquisition of Valencia Technologies
Boston Scientific Buys $1.5B Stake in TAVR Developer MiRus